Literature DB >> 21563035

Urine concentrations of repetitive doses of inhaled salbutamol.

J Elers1, L Pedersen, J Henninge, P Hemmersbach, K Dalhoff, V Backer.   

Abstract

We examined blood and urine concentrations of repetitive doses of inhaled salbutamol in relation to the existing cut-off value used in routine doping control. We compared the concentrations in asthmatics with regular use of beta2-agonists prior to study and healthy controls with no previous use of beta2-agonists. We enrolled 10 asthmatics and 10 controls in an open-label study in which subjects inhaled repetitive doses of 400 microgram salbutamol every second hour (total 1600 microgram), which is the permitted daily dose by the World Anti-Doping Agency (WADA). Blood samples were collected at baseline, 30 min, 1, 2, 3, 4, and 6 h after the first inhalations. Urine samples were collected at baseline, 0-4 h, 4-8 h, and 8-12 h after the first inhalations. Median urine concentrations peaked in the period 4-8 h after the first inhalations in the asthmatics and between 8-12 h in controls and the median ranged from 268 to 611 ng×mL (-1). No samples exceeded the WADA threshold value of 1000 ng×mL (-1) when corrected for the urine specific gravity. When not corrected one sample exceeded the cut-off value with urine concentration of 1082 ng×mL (-1). In conclusion we found no differences in blood and urine concentrations between asthmatic and healthy subjects. We found high variability in urine concentrations between subjects in both groups. The variability between subjects was still present after the samples were corrected for urine specific gravity. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21563035     DOI: 10.1055/s-0031-1273755

Source DB:  PubMed          Journal:  Int J Sports Med        ISSN: 0172-4622            Impact factor:   3.118


  4 in total

1.  Investigation of the Interaction Mechanism between Salbutamol and Human Serum Albumin by Multispectroscopic and Molecular Docking.

Authors:  Ting Zhao; Zihui Liu; Jingmei Niu; Baoxing Lv; Yuliang Xiao; Yuqin Li
Journal:  Biomed Res Int       Date:  2020-02-10       Impact factor: 3.411

2.  Acute impact of inhaled short acting b2-agonists on 5 km running performance.

Authors:  John Dickinson; Jiu Hu; Neil Chester; Mike Loosemore; Greg Whyte
Journal:  J Sports Sci Med       Date:  2014-05-01       Impact factor: 2.988

3.  Model-based meta-analysis of salbutamol pharmacokinetics and practical implications for doping control.

Authors:  Perrine Courlet; Thierry Buclin; Jérôme Biollaz; Irene Mazzoni; Olivier Rabin; Monia Guidi
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2022-03-22

4.  Medical and pharmacological approach to adjust the salbutamol anti-doping policy in athletes.

Authors:  Fabien Pillard; Michel Lavit; Valérie Lauwers Cances; Jacques Rami; Georges Houin; Alain Didier; Daniel Rivière
Journal:  Respir Res       Date:  2015-12-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.